Prospective Grant of an Exclusive Patent License: Dimethyl Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory Diseases

ローカル自動翻訳 · 情報源の原言語

概要

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Center for Advancing Translational Sciences (NCATS), both institutes of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Autala Bio Inc., A Civala Company ("Autala"), incorporated in Delaware.

情報源の原言語: Federal Register — Health and Human Services原文の発表を開く →

Prospective Grant of an Exclusive Patent License: Dimethyl Synaptamide for the Treatment of Autoimmune Disorders and Inflammatory Diseases

Center for Scientific Review; エンタカの更にしたモーバーにをきだ

Office of the National Coordinator for Health Information Technology; Health Information Technology Advisory Committee; エンタイントにそすにしたプログルにしたプログにプログを定义にしたプログに。